New chemo cocktail shows promise for rare childhood brain cancer
NCT ID NCT01270724
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a new combination of chemotherapy drugs (gemcitabine, paclitaxel, and oxaliplatin, or GemPOx) followed by high-dose chemotherapy and a stem cell transplant in 10 patients with recurrent or progressive intracranial germ cell tumors. The goal was to see how well the tumors responded to the initial chemo and whether patients could then proceed to the more intensive transplant phase. The study is completed, but results are not yet widely reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gemcitabine, paclitaxel, and oxaliplatin (GemPOx) followed by high-dose chemotherapy and autologous stem cell rescue
- What this could lead to
- If successful, this could offer a treatment option for children with recurrent brain germ cell tumors that have not responded to standard therapy.
- What could go wrong
- This is a very small, early-phase trial with only 10 participants. The combination chemotherapy is intensive and carries significant side effects, and it is not yet known if it will improve long-term survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CNS GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
New York University Langone Medical Center
New York, New York, 10016, United States
-
Phoenix Children's Hospital
Phoenix, Arizona, 85016, United States
-
The Ohio State University Wexner Medical Center_The James Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.